Shingles Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

"Shingles Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Shingles Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Shingles Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Shingles Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Shingles treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Shingles market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn More about the Clinical and Commercial Development Activities in the Shingles Therapeutics Domain:
https://www.delveinsight.com/report-store/shingles-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/shingles-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Shingles Therapeutics Market Assessment
Shingrix vaccine has been approved by the US FDA to prevent shingles and is recommended for adults aged 50 years and older. Other than this vaccine, Shingles' treatments include several antiviral drugs such as famciclovir or valacyclovir. These drugs do not cure the disease, but can help relieve shingles symptoms and shorten their duration. Pain-relieving drugs, anti-inflammation drugs, narcotic medications, and others are also prescribed to treat the symptoms. Several major pharma and biotech giants are developing novel therapies to improve the treatment scenario further.

The Leading Companies in the Shingles Therapeutics Market Include:
• Maruho
• Nobelpharma
• Curevo
• NanoViricides
• GlaxoSmithKline
• Novartis
And Many Others

Shingles Emerging and Market Therapies Covered in the Report Include:
• Fostoin: Nobelpharma
• CRV-101: Curevo
• NV-HHV-101: NanoViricides
• Famvir (famciclovir): Novartis
• Valtrex (valacyclovir): GlaxoSmithKline
• Amenalief (amenamevir): Maruho
• Shingrix: GlaxoSmithKline
And Many More

Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/shingles-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Shingles Current Treatment Patterns
4. Shingles - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Shingles Late-Stage Products (Phase-III)
7. Shingles Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Shingles Discontinued Products
13. Shingles Product Profiles
14. Shingles Key Companies
15. Shingles Key Products
16. Dormant and Discontinued Products
17. Shingles Unmet Needs
18. Shingles Future Perspectives
19. Shingles Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/shingles-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.